自引率: 7.7%
被引量: 21996
通过率: 暂无数据
审稿周期: 2.67
版面费用: 暂无数据
国人发稿量: 11
投稿须知/期刊简介:
Subject matter may relate to the broad field of rheumatology, rehabilitation medicine, immunology, infectious diseases or orthopedic subjects pertaining to the rheumatic diseases.
期刊描述简介:
First published in 1974, The Journal of Rheumatology is a monthly international serial edited by Earl D. Silverman. The Journal features peer-reviewed research articles on clinical subjects from scientists working in rheumatology and related fields, with the support of our esteemed Editorial Committee and Editorial Board. According to The Canadian Essential Journal Study, The Journal of Rheumatology is ranked among the top 3 essential publications for rheumatology. In fact, 74% of rheumatologists consider The Journal of Rheumatology an essential journal, making it the top journal in the specialty. The Journal of Rheumatology publishes timely clinical research papers every month, both in print and online. With thousands of citations per year, The Journal of Rheumatology’s influence and reach extends to over 3600 subscribers globally and to all active members of the Canadian Rheumatology Association, including rheumatology residents and trainees. Since it was established over 40 years ago, The Journal of Rheumatology’s content remains highly relevant to rheumatologists because of the emphasis on continuity while embracing innovation. With over 1600 submissions a year from over 50 countries, each issue of The Journal of Rheumatology includes original clinical research articles, metaanalyses, systematic reviews, editorials, historical vignettes, case reports, and letters by world-renowned experts studying drug therapy, patient-reported outcomes, discovery of therapeutic targets in the treatment of rheumatic diseases such as rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, osteoarthritis, and other rheumatic and musculoskeletal diseases. The Journal of Rheumatology features proceedings of national and international conferences or symposia presented by renowned rheumatologists from Canada and abroad in The Journal of Rheumatology Supplements. These timely supplements typically highlight reports on the mechanisms of rheumatic diseases and updates on emerging therapies.
-
Psychosocial Factors Significantly Contribute to Joint Pain Persistence in Psoriatic Arthritis.
被引量：- 发表：1970
-
Dr Singer et al reply.
被引量：- 发表：1970
-
Quality and Characteristics of Pediatric Rheumatology Content on Social Media: Toward a New Era of Education for Patients and Caregivers?
被引量：1 发表：1970
-
Factors Associated With an Electronic Health Record-Based Definition of Postacute Sequelae of COVID-19 in Patients With Systemic Autoimmune Rheumatic Disease.
Many individuals with rheumatic disease are at higher risk for severe acute coronavirus disease 2019 (COVID-19). We aimed to evaluate risk factors for postacute sequelae of COVID-19 (PASC) using an electronic health record (EHR)-based definition. We identified patients with prevalent rheumatic diseases and COVID-19 within the Mass General Brigham healthcare system. PASC was defined by the International Classification of Diseases, 10th revision (ICD-10) codes, relevant labs, vital signs, and medications at least 30 days following the first COVID-19 infection. Patients were followed until the earliest of incident PASC, repeat COVID-19 infection, 1 year of follow-up, death, or February 19, 2023. We used multivariable Cox regression to estimate the association of baseline characteristics with PASC risk. Among 2459 patients (76.37% female, mean age 57.4 years), the most common incident PASC manifestations were cough (14.56%), dyspnea (12.36%), constipation (11.39%), and fatigue (10.70%). Serious manifestations including acute coronary disease (4.43%), thromboembolism (3.09%), hypoxemia (3.09%), stroke (1.75%), and myocarditis (0.12%) were rare. The Delta wave (adjusted hazard ratio [aHR] 0.63, 95% CI 0.49-0.82) and Omicron era (aHR 0.50, 95% CI 0.41-0.62) were associated with lower risk of PASC than the early pandemic period (March 2020-June 2021). Age, obesity, comorbidity burden, race, and hospitalization for acute COVID-19 infection were associated with greater risk of PASC. Glucocorticoid (GC) use (aHR 1.19, 95% CI 1.05-1.34 compared to no use) was associated with greater risk of PASC. Among patients with rheumatic diseases, following their first COVID-19 infection, we found a decreased risk of PASC over calendar time using an EHR-based definition. Aside from GCs, no specific immunomodulatory medications were associated with increased risk, and risk factors were otherwise similar to those seen in the general population.
被引量：1 发表：1970
-
Orbital and Optic Nerve Sheath Involvement and Pupil-Involving Cranial Nerve III Palsy in Giant Cell Arteritis.
被引量：- 发表：1970
